Linvencorvir

• CAT Number: I045103
• CAS Number: 1808248-05-6
• Molecular Formula: C29H35FN6O5S
• Molecular Weight: 598.69
• Purity: ≥95%
• Synonyms: 3-[(8aS)-7-[[(4S)-5-ethoxycarbonyl-4-(3-fluoro-2-methylphenyl)-2-(1,3-thiazol-2-yl)-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimethylpropanoic acid
• InChI: InChI=1S/C29H35FN6O5S/c1-5-41-26(37)22-21(15-34-10-11-36-18(13-34)14-35(28(36)40)16-29(3,4)27(38)39)32-24(25-31-9-12-42-25)33-23(22)19-7-6-8-20(30)17(19)2/h6-9,12,18,23H,5,10-11,13-16H2,1-4H3,(H,32,33)(H,38,39)/t18-,23-/m0/s1
• InChIKey: YLJBFYZGSKMBEZ-MBSDFSHPSA-N
• SMILES: CCOC(=O)C1=C(NC(=N[C@H]1C2=C(C(=CC=C2)F)C)C3=NC=CS3)CN4CCN5[C@@H](C4)CN(C5=O)CC(C)(C)C(=O)O

Linvencorvir（Cat No.:I045103）is an investigational antiviral agent targeting hepatitis B virus (HBV), designed as a core protein allosteric modulator (CpAM). By disrupting the assembly of HBV nucleocapsids, Linvencorvir interferes with viral replication and reduces the formation of covalently closed circular DNA (cccDNA), a key reservoir for chronic infection. It is being developed as part of combination regimens aimed at achieving functional cure in chronic HBV patients. Linvencorvir exhibits potent antiviral activity with favorable oral bioavailability. Supplied for research on HBV biology, CpAM mechanisms, and curative antiviral strategies.